Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulinastatin for unliquefied pyogenic liver abscess with septic shock
ChiCTR2200066693Phase 4Recruiting
- Sponsor
- Affiliated Huai'an Hospital of Xuzhou Medical University
- Start
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of ulinastatin in pyogenic liver abscess (PLA) and septic shock, sponsored by Affiliated Huai'an Hospital of Xuzhou Medical University. Primary endpoints: White blood cell count, Lactic acid and 7 more. Started Jan 2018; status: recruiting.
02
Drugs
ulinastatin
03
Conditions
pyogenic liver abscess (PLA)septic shock
Beyond the preview
Go deeper on ChiCTR2200066693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066693.